# RAPP (Rapport Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Rapport Therapeutics, Inc. reported $418.6M in total assets and a net loss of $150.5M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/RAPP
- Markdown: https://convexityos.com/fundamentals/RAPP.md
- SEC CIK: 0002012593
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:28 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002012593&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$167.6M | Operating profit |
| Net Income | FY 2025 | -$150.5M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$3.15 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$121.2M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $395.0M | Total debt: $9.39M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Research & Development | $94.79M | $60.94M | $28.00M |
| Total Operating Expenses | $125.1M | $83.06M | $36.18M |
| **Operating Income** | -$125.1M | -$83.06M | -$36.18M |
| **EBITDA** | -$124.1M | -$82.22M | -$36.07M |
| Interest Income | $13.62M | $12.14M | $2.53M |
| Income Before Tax | -- | -$78.31M | -$34.78M |
| Income Tax Expense | $0 | $0 | $10K |
| **Net Income** | -$111.5M | -$78.31M | -$34.79M |
| Basic EPS | -$2.86 | -$3.78 | -$23.10 |
| **Diluted EPS** | -$2.86 | -$3.78 | -$23.10 |
| Basic Shares Outstanding | 38.9M | 20.7M | 1.5M |
| Diluted Shares Outstanding | 38.9M | 20.7M | 1.5M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $20.00M | -- | $0 | $0 | $0 | -- |
| Research & Development | $34.32M | $51.41M | $32.72M | $30.26M | $22.28M | $22.68M | $19.57M | $17.20M |
| Selling, General & Admin | $9.77M | $9.39M | $11.50M | -- | $7.71M | $6.82M | $7.54M | -- |
| Total Operating Expenses | $44.09M | $60.81M | $44.22M | $38.51M | $29.99M | $29.50M | $27.11M | $23.52M |
| **Operating Income** | -$44.09M | -$60.81M | -$24.21M | -$38.51M | -$29.99M | -$29.50M | -$27.11M | -$23.52M |
| **EBITDA** | -$43.89M | -$60.59M | -$23.99M | -$38.24M | -$29.73M | -$29.24M | -$26.86M | -$23.26M |
| Interest Income | $3.85M | $4.19M | $4.36M | $4.75M | $3.06M | $2.76M | $3.04M | $3.54M |
| **Net Income** | -$40.23M | -$56.62M | -$19.86M | -$33.76M | -$26.93M | -$26.73M | -$24.06M | -$19.98M |
| Basic EPS | -$0.84 | -$1.19 | -$0.42 | -- | -$0.71 | -$0.75 | -$0.68 | -- |
| **Diluted EPS** | -$0.84 | -$1.19 | -$0.42 | -- | -$0.71 | -$0.75 | -$0.68 | -- |
| Basic Shares Outstanding | 47.8M | 47.5M | 47.2M | -- | 37.9M | 35.4M | 35.3M | -- |
| Diluted Shares Outstanding | 47.8M | 47.5M | 47.2M | -- | 37.9M | 35.4M | 35.3M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $52.65M | $56.80M | $70.17M |
| Short-Term Investments | $437.9M | $248.5M | $77.31M |
| **Cash & Short-Term Investments** | $490.5M | $305.3M | $147.5M |
| Accounts Receivable, Net | $0 | -- | -- |
| **Total Current Assets** | $498.6M | $309.8M | $150.9M |
| Property, Plant & Equipment, Net | $2.98M | $3.53M | $1.92M |
| Other Non-Current Assets | $985K | $160K | $551K |
| **Total Non-Current Assets** | $13.87M | $5.13M | $4.55M |
| **Total Assets** | $512.4M | $314.9M | $155.4M |
| Accounts Payable | $4.19M | $1.95M | $2.50M |
| **Total Current Liabilities** | $19.05M | $8.77M | $8.80M |
| **Total Non-Current Liabilities** | $8.73M | $739K | $5.68M |
| **Total Liabilities** | $27.78M | $9.51M | $14.48M |
| **Total Debt (incl. Leases)** | $11.48M | $1.48M | $2.15M |
| Common Stock | $48K | $37K | $4.0K |
| Retained Earnings | -$235.2M | -$123.7M | -$45.44M |
| Accumulated Other Comp. Income | $546K | -$522K | $4.0K |
| **Total Stockholders' Equity** | $484.7M | $305.4M | -$25.63M |
| Total Equity | $484.7M | $305.4M | -$25.63M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $74.75M | $63.61M | $78.06M | $52.65M | $251.4M | $55.07M | $57.60M | $56.80M |
| Short-Term Investments | $320.3M | $372.5M | $398.7M | $437.9M | $261.7M | $205.4M | $227.8M | $248.5M |
| **Cash & Short-Term Investments** | $395.0M | $436.1M | $476.8M | $490.5M | $513.0M | $260.4M | $285.4M | $305.3M |
| Accounts Receivable, Net | $171K | $293K | $58K | $0 | -- | -- | -- | -- |
| **Total Current Assets** | $407.4M | $446.9M | $484.7M | $498.6M | $520.7M | $270.2M | $291.0M | $309.8M |
| Property, Plant & Equipment, Net | $1.96M | $2.34M | $2.52M | $2.98M | $3.12M | $3.17M | $3.40M | $3.53M |
| Other Non-Current Assets | $1.09M | $1.06M | $1.06M | $985K | $1.07M | $1.03M | $211K | $160K |
| **Total Non-Current Assets** | $11.18M | $12.13M | $12.90M | $13.87M | $14.66M | $15.25M | $11.09M | $5.13M |
| **Total Assets** | $418.6M | $459.0M | $497.6M | $512.4M | $535.3M | $285.5M | $302.1M | $314.9M |
| Accounts Payable | $1.72M | $2.80M | $6.56M | $4.19M | $3.23M | $3.18M | $2.14M | $1.95M |
| **Total Current Liabilities** | $20.30M | $28.42M | $17.90M | $19.05M | $14.32M | $11.88M | $9.38M | $8.77M |
| **Total Non-Current Liabilities** | $7.07M | $7.63M | $8.19M | $8.73M | $9.39M | $10.10M | $6.83M | $739K |
| **Total Liabilities** | $27.37M | $36.06M | $26.09M | $27.78M | $23.71M | $21.98M | $16.22M | $9.51M |
| **Total Debt (incl. Leases)** | $9.39M | $10.11M | $10.80M | $11.48M | $11.87M | $11.86M | $7.84M | $1.48M |
| Common Stock | $48K | $48K | $48K | $48K | $48K | $37K | $37K | $37K |
| Retained Earnings | -$351.9M | -$311.7M | -$255.1M | -$235.2M | -$201.5M | -$174.5M | -$147.8M | -$123.7M |
| Accumulated Other Comp. Income | -$2.12M | -$1.27M | -$505K | $546K | $145K | -$76K | -$95K | -$522K |
| **Total Stockholders' Equity** | $391.2M | $422.9M | $471.5M | $484.7M | $511.6M | $263.5M | $285.8M | $305.4M |
| Total Equity | $391.2M | $422.9M | $471.5M | $484.7M | $511.6M | $263.5M | $285.8M | $305.4M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$111.5M | -$78.31M | -$34.79M |
| Depreciation & Amortization | $1.02M | $839K | $112K |
| Stock-Based Compensation | $18.86M | $10.23M | $3.52M |
| Change in Payables | $2.21M | -$346K | $856K |
| **Operating Cash Flow** | -$87.47M | -$64.83M | -$27.18M |
| Capital Expenditure | -$616K | -$2.40M | -$1.64M |
| **Free Cash Flow** | -$88.09M | -$67.23M | -$28.82M |
| Purchases of Investments | -$354.8M | -$377.5M | -$77.22M |
| Sales & Maturities of Investments | $167.9M | $209.8M | -- |
| **Investing Cash Flow** | -$187.5M | -$170.1M | -$78.86M |
| Common Stock Issued | -- | -- | $54K |
| **Financing Cash Flow** | $270.8M | $221.6M | $145.1M |
| **Net Change in Cash** | -$4.16M | -$13.34M | $39.09M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$40.23M | -$56.62M | -$19.86M | -$33.76M | -$26.93M | -$26.73M | -$24.06M | -$19.98M |
| Depreciation & Amortization | $198K | $212K | $227K | $265K | $256K | $252K | $244K | $260K |
| Stock-Based Compensation | $7.63M | $7.20M | $6.96M | $5.69M | $4.74M | $4.39M | $4.04M | $3.21M |
| Change in Receivables | $122K | -$235K | -$58K | -- | $0 | $0 | $0 | -- |
| Change in Payables | -$1.09M | -$3.68M | $2.31M | $1.18M | -$179K | $1.03M | $185K | $648K |
| **Operating Cash Flow** | -$41.63M | -$41.45M | -$13.06M | -$24.70M | -$17.46M | -$25.07M | -$20.24M | -$14.45M |
| Capital Expenditure | $0 | -$78K | -$86K | -$169K | -$134K | -$22K | -$291K | -$226K |
| **Free Cash Flow** | -$41.63M | -$41.53M | -$13.15M | -$24.87M | -$17.60M | -$25.09M | -$20.53M | -$14.67M |
| Purchases of Investments | -$14.39M | -$39.67M | -$30.37M | -$197.1M | -$101.6M | -$12.86M | -$43.23M | -$84.56M |
| Sales & Maturities of Investments | $65.25M | $65.16M | $58.32M | $22.92M | $44.98M | $35.48M | $64.56M | $116.7M |
| **Investing Cash Flow** | $51.06M | $25.60M | $37.94M | -$174.3M | -$56.78M | $22.60M | $21.03M | $31.93M |
| **Financing Cash Flow** | $1.71M | $1.41M | $531K | $311K | $270.5M | -$63K | $5.0K | $7.0K |
| **Net Change in Cash** | $11.14M | -$14.44M | $25.41M | -$198.7M | $196.3M | -$2.54M | $799K | $17.49M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Return on Equity (ROE) | -23.0% | -25.6% | -- |
| Return on Assets (ROA) | -21.8% | -24.9% | -22.4% |
| Current Ratio | 26.17x | 35.34x | 17.14x |
| Quick Ratio | 25.75x | 34.82x | 16.75x |
| Debt to Equity | 0.02x | 0.00x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -38.5% | -32.4% | -22.8% | -23.0% | -19.1% | -33.5% | -27.9% | -25.6% |
| Return on Assets (ROA) | -35.9% | -29.9% | -21.6% | -21.8% | -18.3% | -30.9% | -26.4% | -24.9% |
| Current Ratio | 20.07x | 15.72x | 27.08x | 26.17x | 36.37x | 22.75x | 31.01x | 35.34x |
| Quick Ratio | 19.46x | 15.35x | 26.64x | 25.75x | 35.83x | 21.92x | 30.42x | 34.82x |
| Debt to Equity | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | 0.05x | 0.03x | 0.00x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
